GT20029 — Safety, Research, Risks & Legal Status

Not medical advice. GT20029 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	GT-20029; AR-PROTAC; androgen receptor PROTAC (topical)
Category	Research Chemical
Drug class	First-in-class topical androgen receptor PROTAC (proteolysis-targeting chimera)
Developer	Suzhou Kintor Pharmaceutical Limited (China)
Current highest trial phase	Phase 3 (China, AGA); Phase 2 (US, acne; ongoing)
Formulation	Topical gel / tincture solution; applied to scalp or affected skin
Primary endpoints met	Phase 2 China AGA (hair regrowth, 12 weeks) and Phase 2 China acne vulgaris - both statistically significant vs. placebo
Systemic testosterone effect	No clinically meaningful change in serum testosterone observed in Phase 1 or Phase 2 data
US legal status	Not FDA-approved. GT20029 is an investigational new drug (IND) in active clinical development. It holds IND designation from China's National Medical Products Administration (NMPA, granted February 2021). US Phase 1 trials have been completed under US IND; US Phase 2 for acne is ongoing. It is not approved for any indication in the US or EU, is not available commercially, and is not lawfully sold as a supplement or research chemical. Possession outside of a sanctioned clinical trial carries regulatory risk.

What is GT20029?

GT20029 is a first-in-class topical androgen receptor (AR) proteolysis-targeting chimera (PROTAC) developed by Suzhou Kintor Pharmaceutical Limited. PROTACs are bivalent small molecules that simultaneously bind a target protein and an E3 ubiquitin ligase, recruiting the cell's own proteasome machinery to degrade the target. GT20029 is designed for topical application to skin, enabling localized AR degradation in hair follicles and sebaceous tissue with minimal systemic exposure. It is under investigation for androgenetic alopecia (AGA, male-pattern hair loss) and acne vulgaris. As of mid-2025, Phase 2 trials in China have reported positive topline results for both indications; Phase 3 is advancing in China for AGA, and US trials remain in earlier stages.

How it works

GT20029 operates through the PROTAC mechanism: the molecule contains two binding warheads linked by a chemical linker. One end binds the androgen receptor; the other recruits an E3 ubiquitin ligase. Proximity between the AR and the E3 ligase results in polyubiquitination of the AR, flagging it for degradation by the 26S proteasome. Unlike conventional AR antagonists (which only block receptor function while the protein remains present), GT20029 physically eliminates AR protein. Critically, each PROTAC molecule is released after the target is degraded and can then engage another AR molecule - a catalytic effect that theoretically enables activity at lower molar concentrations than occupancy-based inhibitors. Applied topically, GT20029 acts locally in peripheral skin tissue. Pharmacokinetic data from Phase 1 show low and variable systemic absorption with no dose-proportional accumulation, and no clinically meaningful changes in serum testosterone - consistent with a primarily local mechanism of action. The proposed clinical benefit in AGA is blockade of AR-driven follicle miniaturization; in acne, suppression of AR-mediated sebum overproduction.

Background & history

GT20029 was developed by Suzhou Kintor Pharmaceutical, a China-based biopharmaceutical company. Kintor filed for IND status with China's NMPA in early 2021 (granted February 2, 2021), designating it the world's first topical PROTAC compound to enter clinical development. US Phase 1 trials were initiated under NCT05428449 and NCT06468579, enrolling a combined n=123 participants across US and China sites; top-line Phase 1 results (safety and PK) were reported as positive in early 2023. Phase 2 trials in China for AGA and acne both subsequently met their primary endpoints. In 2024-2025, Kintor announced advancement to Phase 3 in China for AGA, while US Phase 2 for acne remains ongoing. A peer-reviewed Phase 2 publication appeared in Expert Opinion on Investigational Drugs in 2025. The chemical structure remains proprietary and has not been disclosed in the public literature.

What the research says

Clinical data are more mature than is typical for a compound at this stage, owing to the China-led development timeline. Phase 1 (US and China, n=123): demonstrated acceptable safety and tolerability with a clean PK profile - low systemic exposure, no dose-proportional accumulation, stable systemic laboratory parameters. Phase 2 China AGA (multicenter, randomized, double-blind, placebo-controlled): four active doses tested; statistically significant hair regrowth at 12 weeks vs. placebo; adverse event rates comparable to placebo; no treatment-related serious adverse events; no discontinuations due to drug-related AEs; no adverse sexual events. Phase 2 China acne vulgaris: met primary efficacy endpoint with statistically significant results (detailed data not fully published as of mid-2025). US Phase 2 for acne is ongoing. Phase 3 in China for AGA is advancing. No head-to-head data vs. finasteride or minoxidil are available. Long-term safety data beyond 12-week Phase 2 windows are not yet published. US Phase 3 has not been initiated. Regulatory approval in any jurisdiction remains years away under optimistic projections.

Reported effects

Topical AR degradation via PROTAC/proteasome mechanism (demonstrated in preclinical and human PK studies)
Statistically significant hair regrowth in androgenetic alopecia at 12 weeks (Phase 2, China; placebo-controlled)
Statistically significant acne efficacy (Phase 2, China; primary endpoint met)
Minimal systemic AR suppression - no clinically meaningful changes in serum testosterone or sexual function reported in trials
Localized action at skin follicles and sebaceous tissue without systemic androgen blockade (based on PK data)

Dosing & administration (informational)

Phase 2 AGA trials tested four dose levels applied topically (gel or tincture formulation); specific concentrations and volumes are not fully disclosed in public summaries. The trial design used once-daily topical application in most published descriptions. These are literature observations from controlled trials only. No dosing protocol can be derived for non-trial use, and no self-administration regimen exists or is appropriate given unapproved status. Consult a licensed clinician and refer to active trial protocols at ClinicalTrials.gov for accurate dosing parameters.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Phase 1 (n=123, US/China): characterized as safe and well-tolerated with acceptable PK profile
Phase 2 AGA: adverse event rate comparable to placebo; no treatment-related serious adverse events; no drug-related discontinuations
Most common adverse event: application-site pruritus (7.3% active vs. similar placebo rates in published data)
No adverse sexual events (erectile dysfunction, libido changes) reported - distinguishing it from systemic 5-alpha reductase inhibitors
Systemic parameters (hematology, metabolic chemistry, urinalysis, ECG) remained stable across Phase 1 and Phase 2
Only serious AE identified: one optic disk vascular disorder in the placebo group only - not considered drug-related
Long-term safety data (beyond 12 weeks) not yet available; Phase 3 and longer follow-up studies are needed

Drug & supplement interactions

N
o
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
a
r
e
a
v
a
i
l
a
b
l
e
i
n
t
h
e
p
u
b
l
i
c
l
i
t
e
r
a
t
u
r
e
b
e
y
o
n
d
t
h
e
P
h
a
s
e
1
/
2
t
r
i
a
l
s
a
f
e
t
y
s
u
m
m
a
r
i
e
s
.
S
y
s
t
e
m
i
c
a
b
s
o
r
p
t
i
o
n
i
s
l
o
w
a
n
d
v
a
r
i
a
b
l
e
;
t
h
e
o
r
e
t
i
c
a
l
d
r
u
g
-
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
r
i
s
k
v
i
a
C
Y
P
o
r
t
r
a
n
s
p
o
r
t
e
r
p
a
t
h
w
a
y
s
c
a
n
n
o
t
b
e
a
s
s
e
s
s
e
d
w
i
t
h
o
u
t
p
u
b
l
i
s
h
e
d
m
e
t
a
b
o
l
i
c
p
r
o
f
i
l
i
n
g
d
a
t
a
.
C
o
-
a
p
p
l
i
c
a
t
i
o
n
o
f
o
t
h
e
r
t
o
p
i
c
a
l
a
g
e
n
t
s
t
o
t
h
e
s
a
m
e
s
c
a
l
p
o
r
s
k
i
n
a
r
e
a
d
u
r
i
n
g
t
r
i
a
l
s
h
a
s
n
o
t
b
e
e
n
c
h
a
r
a
c
t
e
r
i
z
e
d
.
N
o
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
h
a
v
e
b
e
e
n
p
u
b
l
i
s
h
e
d
.

Who should avoid it

Self-administration outside sanctioned clinical trials - compound is unapproved and not available for personal use
Compounded or grey-market sources claiming to offer GT20029 - chemical identity and purity cannot be verified
Use in individuals with hypersensitivity to any component of the investigational formulation
Application to broken, inflamed, or infected skin beyond what trial protocols specify
Concurrent use of systemic androgens or anti-androgens without clinical supervision, given lack of interaction data

How it is commonly combined

No published data on combination use with other agents (e.g., minoxidil, finasteride, dutasteride, or topical retinoids for acne). Combining unapproved investigational compounds with other medications in a self-directed manner is inadvisable and potentially unsafe given absent interaction data.

Legal & regulatory. Not FDA-approved. GT20029 is an investigational new drug (IND) in active clinical development. It holds IND designation from China's National Medical Products Administration (NMPA, granted February 2021). US Phase 1 trials have been completed under US IND; US Phase 2 for acne is ongoing. It is not approved for any indication in the US or EU, is not available commercially, and is not lawfully sold as a supplement or research chemical. Possession outside of a sanctioned clinical trial carries regulatory risk.

Quality & harm reduction

Safer, legal alternative we recommend

Botani-GLOW Up. For the same hair-growth goal, our topical botanical hair serum is a legal, over-the-counter option you can actually buy today.

See our recommended pick

Find GT20029 →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

What makes GT20029 different from finasteride or topical minoxidil for hair loss?

Finasteride is a systemic 5-alpha reductase inhibitor that reduces DHT levels throughout the body, which carries a risk of sexual side effects and is taken orally. Minoxidil is a vasodilator with an incompletely understood mechanism. GT20029 is a topical PROTAC that physically degrades androgen receptor protein locally in scalp tissue, theoretically without meaningfully suppressing systemic androgen signaling. Phase 2 trial data showed no adverse sexual events and no clinically significant change in serum testosterone - though head-to-head comparative trials with finasteride or minoxidil do not yet exist.

Can I obtain or use GT20029 now?

No. GT20029 is not FDA-approved, not sold commercially, and not available through legitimate consumer channels in any jurisdiction. It exists only within controlled clinical trials. Claims by any third-party vendor to supply this compound cannot be verified and should be treated with significant skepticism regarding identity and safety.

What dose should I use?

This is not a question that can be answered here. GT20029 is an unapproved investigational drug. No dosing protocol for self-administration exists or is appropriate. If you are interested in access, search for active trials at ClinicalTrials.gov using the terms 'GT20029' or 'GT-20029,' and consult a licensed dermatologist or clinical investigator.

Does GT20029 cause the same sexual side effects as finasteride?

Based on Phase 1 and Phase 2 trial data available as of mid-2025, no adverse sexual events were reported in participants receiving active GT20029. Serum testosterone levels showed no clinically meaningful change. The proposed mechanism - local AR degradation in skin with minimal systemic absorption - would theoretically limit the systemic androgenic suppression that drives finasteride-associated sexual adverse effects. However, Phase 3 data and long-term safety follow-up have not yet been published, so definitive conclusions about rare or delayed sexual side effects cannot be drawn.

When might GT20029 become available as an approved drug?

Phase 3 trials are advancing in China for AGA; US Phase 2 for acne is ongoing as of mid-2025. A realistic regulatory timeline to potential approval in China is uncertain; US FDA approval would require successful completion of US Phase 2 and Phase 3 programs. An optimistic estimate places any approval 2-5 or more years away, and regulatory outcomes cannot be predicted.

Has GT20029 been published in peer-reviewed literature?

Yes, at least one peer-reviewed publication exists: a Phase 2 AGA study published in Expert Opinion on Investigational Drugs in 2025. Clinical trial registrations NCT05428449, NCT06468579, and NCT06692465 are publicly accessible at ClinicalTrials.gov. PubMed searches for 'GT20029 PROTAC androgenetic alopecia' or 'androgen receptor degrader topical' are the recommended starting points for primary literature.

References & further reading

ClinicalTrials.gov: NCT05428449 (US Phase 1, AGA and acne)
ClinicalTrials.gov: NCT06468579 (US Phase 1, safety and pharmacokinetics)
ClinicalTrials.gov: NCT06692465 (China Phase 2, androgenetic alopecia)
PubMed: GT20029 PROTAC androgenetic alopecia phase 2
PubMed: androgen receptor degrader topical PROTAC hair loss